Organogenesis Holdings (ORGO) Non Operating Interest Expenses (2017 - 2026)

Organogenesis Holdings has reported Non Operating Interest Expenses for 10 years, with the latest figure at -$138000.0 in Q2 2026.

• On a quarterly basis, Non Operating Interest Expenses rose 79.37% year-over-year to -$138000.0 in Q2 2026; TTM through Jun 2026 was -$1.2 million, a 4.18% increase from a year earlier, with the FY2025 full-year figure at -$2.3 million, down 247.73% from the prior year.
• Non Operating Interest Expenses was -$138000.0 for Q2 2026 at Organogenesis Holdings, up from -$380000.0 in the prior quarter.
• The five-year high for Non Operating Interest Expenses was $737000.0 in Q1 2022, with the low at -$961000.0 in Q1 2025.
• Average Non Operating Interest Expenses over 5 years is $163500.0, with a median of $457500.0 recorded in 2023.
• The sharpest annual moves came in 2023 and 2025: Non Operating Interest Expenses surged 1773.33% in 2023, then slumped 286.96% in 2025.
• Over 5 years, Non Operating Interest Expenses stood at -$30000.0 in 2022, then soared by 1773.33% to $502000.0 in 2023, then slumped by 112.15% to -$61000.0 in 2024, then plunged by 286.89% to -$236000.0 in 2025, then surged by 41.53% to -$138000.0 in 2026.
• The last three Non Operating Interest Expenses figures came in at -$138000.0 (Q2 2026), -$380000.0 (Q1 2026), and -$236000.0 (Q4 2025), per Business Quant data.